{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T11:35:31Z","timestamp":1771068931260,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ejps.2016.05.031","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T20:47:29Z","timestamp":1464727649000},"page":"96-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Effect of solubility enhancement on nasal absorption of meloxicam"],"prefix":"10.1016","volume":"95","author":[{"given":"Tam\u00e1s","family":"Horv\u00e1th","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Ambrus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gergely","family":"V\u00f6lgyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1ria","family":"Budai-Sz\u0171cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1rp\u00e1d","family":"M\u00e1rki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Sipos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csilla","family":"Bartos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienn B.","family":"Seres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Sztojkov-Ivanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisztina","family":"Tak\u00e1cs-Nov\u00e1k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erzs\u00e9bet","family":"Cs\u00e1nyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1571-7579","authenticated-orcid":false,"given":"R\u00f3bert","family":"G\u00e1sp\u00e1r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piroska","family":"Szab\u00f3-R\u00e9v\u00e9sz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2016.05.031_bb0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijpharm.2009.07.009","article-title":"Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam","volume":"381","author":"Ambrus","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2016.05.031_bb0010","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1359-6446(02)02452-2","article-title":"Permeability issues in nasal drug delivery","volume":"7","author":"Arora","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2016.05.031_bb0015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jpba.2007.10.030","article-title":"Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound","volume":"46","author":"Baka","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2016.05.031_bb0020","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijpharm.2015.06.046","article-title":"Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles","volume":"491","author":"Bartos","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2016.05.031_bb9000","first-page":"576","article-title":"Pharmacokinetics of meloxicam in animals with relevance to humans","volume":"26","author":"Busch","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2016.05.031_bb0025","unstructured":"Billotte, A., Dunn, P. J., Henry, B. T., Marshall, P. V., Woods, J. J., 1999. Intranasal formulations for treating sexual disorders. Canadian Intellectual Property Office CA 2275554 C. Date of Patent: 1999.12.22."},{"key":"10.1016\/j.ejps.2016.05.031_bb0035","unstructured":"Castile, J.D., Lin, W., Smith, A., Watts, P.J., 2005. Intranasal formulation of meloxicam. World Intellectual Property Organization patent WO 2005021041 A1. Date of Patent: 2005.03.10."},{"key":"10.1016\/j.ejps.2016.05.031_bb0040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1023\/A:1015812615635","article-title":"A simple rheological method for the in vitro assessment of mucin-polymer bioadhesive bond strength","volume":"7","author":"Hassan","year":"1990","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2016.05.031_bb0045","first-page":"1","article-title":"Investigation of permeability of intranasal formulations using Side-Bi-Side\u2122 horizontal diffusion cell","volume":"85","author":"Horv\u00e1th","year":"2015","journal-title":"Acta Pharm. Hung."},{"key":"10.1016\/j.ejps.2016.05.031_bb0050","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijpharm.2011.08.007","article-title":"Thermal processing of a poorly water-soluble drug substance exhibiting a high melting point: the utility of KinetiSol\u00ae dispersing","volume":"419","author":"Hughey","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2016.05.031_bb0055","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1471-4159.1997.68010233.x","article-title":"Intranasal administration of the dopaminergic agonists l-dopa, amphetamine, and cocaine increases dopamine activity in the neostriatum: a microdialysis study in the rat","volume":"68","author":"Huston","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejps.2016.05.031_bb0060","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S1359-6446(02)02529-1","article-title":"Nasal drug delivery: new developments and strategies","volume":"7","author":"Illum","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2016.05.031_bb0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jpba.2014.11.005","article-title":"Microstructural analysis of the fast gelling freeze-dried sodium hyaluronate","volume":"104","author":"Kr\u00fcger-Szab\u00f3","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2016.05.031_bb0070","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.powtec.2011.05.018","article-title":"Study of the parameters influencing the co-grinding process for the production of meloxicam nanoparticles","volume":"212","author":"K\u00fcrti","year":"2011","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejps.2016.05.031_bb0075","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejps.2013.03.012","article-title":"In vitro and in vivo characterization of meloxicam nanoparticles designed for nasal administration","volume":"50","author":"K\u00fcrti","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2016.05.031_bb0080","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijpharm.2015.05.009","article-title":"Nasal delivery of analgesic ketorolac tromethamine thermo- and ion-sensitive in situ hydrogels","volume":"489","author":"Li","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2016.05.031_bb0085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijpharm.2011.03.050","article-title":"Nanosuspensions of poorly soluble drugs: preparation and development by wet milling","volume":"411","author":"Liua","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2016.05.031_bb0090","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1021\/op900031h","article-title":"Manufacture of high-purity meloxicam via its novel potassium salt monohydrate","volume":"13","author":"Mezei","year":"2009","journal-title":"Org. Process. Res. Dev."},{"key":"10.1016\/j.ejps.2016.05.031_bb0095","unstructured":"Mezei, T., Simig, G., Moln\u00e1r, E., Luk\u00e1cs, G., Porcs-Makkay, M., Volk, B., Hofmann\u00e9 Fekete, V., Nagy, K., Mesterh\u00e1zy, N., Krasznai, Gy., Vereczkeyn\u00e9 Don\u00e1th, Gy., K\u00f6rtv\u00e9lyessy, Gy., P\u00e9csi, \u00c9., 2012. Process for preparation of high-purity meloxicam and meloxicam potassium salt. U.S. Patent No. 8097616 B2. Date of Patent: 2012.01.17."},{"key":"10.1016\/j.ejps.2016.05.031_bb0100","first-page":"801","article-title":"Empirical modeling of the fine particle fraction for carrier-based pulmonary delivery formulations","volume":"10","author":"Pac\u0142awski","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2016.05.031_bb0105","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.eurpolymj.2013.03.017","article-title":"Effect of polymers for aerolization properties of mannitol-based microcomposites containing meloxicam","volume":"49","author":"Pom\u00e1zi","year":"2013","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.ejps.2016.05.031_bb0115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF02530425","article-title":"Intranasal fentanyl for breakthrough cancer pain. A pilot study","volume":"7","author":"Striebel","year":"1993","journal-title":"Schmerz"},{"key":"10.1016\/j.ejps.2016.05.031_bb0120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/bdd.1800","article-title":"In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen","volume":"33","author":"Tsume","year":"2012","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2016.05.031_bb0125","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1016\/j.clinthera.2009.12.015","article-title":"A review of the clinical pharmacokinetics of opioids, benzodiazepines, and antimigraine drugs delivered intranasally","volume":"31","author":"Veldhorst-Janssen","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejps.2016.05.031_bb0130","series-title":"WHO Normative Guidelines on Pain Management: WHO Report 2007","author":"World Health Organization","year":"2007"},{"key":"10.1016\/j.ejps.2016.05.031_bb0135","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Prog. Biomed."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716302123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716302123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T07:30:22Z","timestamp":1718609422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098716302123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":26,"alternative-id":["S0928098716302123"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2016.05.031","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of solubility enhancement on nasal absorption of meloxicam","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2016.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}